Consistent with an ITPKB tumor-suppressor function in human blood cancers, large-scale whole exome sequencing has identified three different ITPKB somatic mutations as candidate CLL drivers in 2% of human patients (164). Here, ITPKB is linked to hematopoietic and lymphoid system neoplasm.